SLC17A2 (solute carrier family 17 member 2) functions as a membrane potential-dependent organic anion transporter that mediates chloride-dependent transport of urate and can actively transport inorganic phosphate into cells via sodium cotransport. The gene has been identified as a novel susceptibility locus for gout through pathway analysis, where genetic variants influence serum urate concentrations and gout risk 1. SLC17A2 demonstrates significant clinical relevance across multiple diseases. In hepatocellular carcinoma, low expression correlates with poor prognosis and is associated with immune cell infiltration patterns 2. The gene shows sex-specific variant patterns in non-alcoholic steatohepatitis, with polymorphisms identified specifically in female samples 3. Additionally, SLC17A2 variants have been associated with lean NAFLD susceptibility 4 and stroke risk in genome-wide association studies 5. In cardiovascular contexts, genetic variants in SLC17A2 show associations with carotid intima-media thickness in Mexican Americans with rheumatoid arthritis 6. The gene also exhibits differential methylation patterns in prostate cancer, being hypomethylated in aggressive versus indolent tumors 7. These findings establish SLC17A2 as a multi-functional transporter with broad clinical implications across metabolic, hepatic, cardiovascular, and oncological diseases.